Notice Number: NOT-DA-15-076

Key Dates
Release Date: September 24, 2015
Estimated Publication Date of Announcement: January 2016
First Estimated Application Due Date: February 5, 2016
Earliest Estimated Award Date: September 2016
Earliest Estimated Start Date: November 2016

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse intends reissue PAR-12-239 "Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 )". Specifically, the nature of the assays are to quantitatively assess a) the level of a subject's exposure to illicit drugs or b) adherence to a test medication regimen.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and projects. 

This Notice is being provided to alert potential applicants that there will be less than 30 days between the open date and the due date for the reissuance of the funding opportunity announcement. Publication of the reissued funding opportunity announcement is expected January 8, 2016, and the first due date will be February 5, 2016.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages investigators with expertise and insights in clinical assessment of point of care assays to begin to consider applying for this new FOA.

In addition, collaborative investigations combining expertise in point of care, quantitative assay development and out-patient clinical research will be encouraged and these investigators should also begin considering applying for this application.

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Aidan Hampson PhD.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-8039
Email: aidan.hampson@nih.gov